Vertex Pharmaceuticals Future Growth

Future criteria checks 3/6

Vertex Pharmaceuticals is forecast to grow earnings and revenue by 10.1% and 8.6% per annum respectively. EPS is expected to grow by 9.7% per annum. Return on equity is forecast to be 21% in 3 years.

Key information

10.1%

Earnings growth rate

9.7%

EPS growth rate

Biotechs earnings growth	25.1%
Revenue growth rate	8.6%
Future return on equity	21.0%
Analyst coverage	Good
Last updated	19 May 2024

Recent future growth updates

Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 08

Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452

Feb 07

Recent updates

Here's Why Shareholders Will Not Be Complaining About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Pay Packet

May 09

Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 08

Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'

Apr 11

Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely

Apr 05

Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth

Mar 21

Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?

Mar 15

Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run

Feb 28

We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings

Feb 22

Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452

Feb 07

Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range

Jan 22

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Jan 15

Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Dec 25

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued

Nov 13

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Oct 02

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate

Jul 31

We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease

Jul 03

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 22% Undervalued

Apr 30

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Apr 03

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 24% Undervalued

Jan 23

If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity

Jan 02

Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 47%?

Oct 24

Vertex to advance two AAT correctors to potentially treat rare, genetic disease

Oct 11

Do Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings Warrant Your Attention?

Oct 02

Vertex in licensing agreement with MaxCyte to use platform for gene editing candidate

Sep 28

Earnings and Revenue Growth Forecasts

NasdaqGS:VRTX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	12,793	5,098	5,510	5,433	24
12/31/2025	11,672	4,462	4,769	4,895	30
12/31/2024	10,754	3,994	4,270	4,961	30
3/31/2024	10,185	4,019	3,479	3,944	N/A
12/31/2023	9,869	3,620	3,279	3,537	N/A
9/30/2023	9,654	3,470	4,205	4,381	N/A
6/30/2023	9,505	3,365	3,879	4,068	N/A
3/31/2023	9,208	3,260	3,890	4,074	N/A
12/31/2022	8,931	3,322	3,925	4,130	N/A
9/30/2022	8,701	3,273	3,814	4,047	N/A
6/30/2022	8,350	3,195	3,787	4,018	N/A
3/31/2022	7,948	2,451	2,451	2,679	N/A
12/31/2021	7,574	2,342	2,409	2,644	N/A
9/30/2021	7,130	2,176	1,919	2,140	N/A
6/30/2021	6,684	1,992	1,777	2,121	N/A
3/31/2021	6,415	2,762	3,048	3,359	N/A
12/31/2020	6,206	2,712	2,994	3,254	N/A
9/30/2020	5,991	2,691	2,979	3,208	N/A
6/30/2020	5,403	2,081	2,557	2,635	N/A
3/31/2020	4,819	1,511	1,983	2,060	N/A
12/31/2019	4,163	1,177	1,494	1,569	N/A
9/30/2019	3,620	2,144	1,363	1,438	N/A
6/30/2019	3,454	2,215	1,413	1,484	N/A
3/31/2019	3,265	2,155	1,258	1,342	N/A
12/31/2018	3,048	2,096	1,175	1,270	N/A
9/30/2018	2,829	647	1,060	1,183	N/A
6/30/2018	2,623	415	682	972	N/A
3/31/2018	2,415	226	554	832	N/A
12/31/2017	2,489	263	N/A	845	N/A
9/30/2017	2,296	196	N/A	762	N/A
6/30/2017	2,131	259	N/A	658	N/A
3/31/2017	2,019	177	N/A	517	N/A
12/31/2016	1,702	-112	N/A	236	N/A
9/30/2016	1,661	-219	N/A	121	N/A
6/30/2016	1,557	-275	N/A	-7	N/A
3/31/2016	1,292	-399	N/A	-158	N/A
12/31/2015	1,032	-556	N/A	-365	N/A
9/30/2015	759	-659	N/A	-576	N/A
6/30/2015	628	-734	N/A	-602	N/A
3/31/2015	600	-704	N/A	-620	N/A
12/31/2014	580	-738	N/A	-573	N/A
9/30/2014	787	-582	N/A	-362	N/A
6/30/2014	830	-530	N/A	-289	N/A
3/31/2014	1,002	-428	N/A	-162	N/A
12/31/2013	1,212	-504	N/A	-61	N/A
9/30/2013	1,195	-559	N/A	-40	N/A
6/30/2013	1,309	-499	N/A	80	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: VRTX's forecast earnings growth (10.1% per year) is above the savings rate (2.4%).

Earnings vs Market: VRTX's earnings (10.1% per year) are forecast to grow slower than the US market (14.6% per year).

High Growth Earnings: VRTX's earnings are forecast to grow, but not significantly.

Revenue vs Market: VRTX's revenue (8.6% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: VRTX's revenue (8.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: VRTX's Return on Equity is forecast to be high in 3 years time (21%)

Vertex Pharmaceuticals Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Vertex Pharmaceuticals Incorporated Re-Iterates Earnings Guidance for the Full Year 2024

Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452

Vertex Pharmaceuticals Incorporated Provides Product Revenue Guidance for the Full Year 2024

Vertex Pharmaceuticals Incorporated Revises Revenue Guidance for the Fiscal 2022

Recent updates

CEO, President & Director notifies of intention to sell stock

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) completed the acquisition of Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders.

Vertex Pharmaceuticals Incorporated Appoints Jennifer Schneider as Independent Director

Here's Why Shareholders Will Not Be Complaining About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Pay Packet

Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Vertex Pharmaceuticals Incorporated Re-Iterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Vertex Pharmaceuticals Announces European Commission Approval for KALYDECO to Treat Infants with Cystic Fibrosis Ages 1 Month and Older

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion.

Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'

Vertex Pharmaceuticals Incorporated to Report Q1, 2024 Results on May 06, 2024

Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 15, 2024

Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely

Vertex Pharmaceuticals Incorporated Announces New Drug Submission for Exagamglogene Autotemcel (Exa-Cel) Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth

Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?

Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run

Vertex Pharmaceuticals Receives CHMP Positive Opinion for KALYDECO for the Treatment of Infants with Cystic Fibrosis Ages 1 Month and Older

We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings

Executive VP & COO notifies of intention to sell stock

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated Announces Positive Results from Pivotal Trials of Vanza Triple Combination Treatment for Cystic Fibrosis

Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452

Full year 2023 earnings: EPS exceeds analyst expectations

Vertex Pharmaceuticals Incorporated Provides Product Revenue Guidance for the Full Year 2024

Vertex Announces Positive Results from the VX-548 Phase 3 Program for the Treatment of Moderate-To-Severe Acute Pain

Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range

Vertex Pharmaceuticals Incorporated to Report Q4, 2023 Results on Feb 05, 2024

Vertex Pharmaceuticals Incorporated Announces US FDA Approval of CASGEVY™ (Exagamglogene Autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Vertex Pharmaceuticals Incorporated Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Kingdom of Saudi

Executive VP & CFO notifies of intention to sell stock

Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Executive Chairman notifies of intention to sell stock

Vertex Pharmaceuticals Incorporated Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy

CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States

Vertex Pharmaceuticals Incorporated Appoints Nancy Thornberry to Its Board of Directors as an Independent Director

Health Canada Grants Market Authorization for KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older

Vertex Pharmaceuticals Incorporated Announces European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5

Vertex Pharmaceuticals Incorporated Announces United Kingdom Medicines and Healthcare Products Regulatory Agency Granted Conditional Marketing Authorization for CASGEVY

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued

Lead Independent Director notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Market Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 To 5 Years With at Least One F508del Mutation

Vertex Pharmaceuticals Incorporated to Report Q3, 2023 Results on Nov 06, 2023

Vertex Pharmaceuticals Incorporated Appoints Michel Lagarde to Its Board of Directors

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Vertex Pharmaceuticals Incorporated Receives Chmp Positive Opinion for Kaftrio® (Ivacaftor/Tezacaftor/Elexacaftor) in Combination with Ivacaftor for Children with Cystic Fibrosis Ages 2 Through 5

Vertex Pharmaceuticals Incorporated Appoints E. Morrey Atkinson, Ph.D., as Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations

Now 20% undervalued after recent price drop

Vertex Pharmaceuticals Incorporated Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate

Now 21% undervalued

Lead Independent Director notifies of intention to sell stock

Vertex Pharmaceuticals Incorporated Announces European Commission Approval for ORKAMBI® (Lumacaftor/Ivacaftor) for the Treatment of Children with Cystic Fibrosis Ages 1 to <2 Years Old

We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease

Insufficient new directors

Vertex Pharmaceuticals Incorporated Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions

Now 20% undervalued

Executive VP & COO notifies of intention to sell stock

Vertex Pharmaceuticals Incorporated and Crispr Therapeutics Announces Positive Results from Pivotal Trials of Exa-Cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce FDA Accepts Biologics License Applications for Exagamglogene Autotemcel (Exa-Cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Now 21% undervalued

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

CEO, President & Director notifies of intention to sell stock

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 22% Undervalued

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Executive VP & CFO notifies of intention to sell stock